Catalyst OrthoScience just pulled off a $15M precision strike that lands cleaner than a surgeon’s final suture. The Naples-based medtech isn’t just padding its balance sheet, it’s reinforcing a foundation built on surgeon-first design and relentless innovation. The raise mixes equity and debt with surgical symmetry, led by RC Capital, with continued backing from Mutual Capital Partners, Dr. Derace Schaffer, and Western Alliance Bank. For a company obsessed with reproducibility, even the cap stack looks biomechanically balanced.
Founded in 2014 by orthopedic surgeon Dr. Steven Goldberg, Catalyst was born from a single operating-room epiphany: shoulder replacement tech hadn’t evolved with the people using it. Dr. Goldberg, Chief of Ortho Surgery at Physicians Regional, built the first prototype on the idea that better design equals better outcomes. Less bone cut, more precision, more natural motion. Fast-forward: 10K+ procedures later, Catalyst’s systems aren’t just implants; they’re extensions of human anatomy.
CEO Carl O’Connell, the operator with 30+ years at Stryker, Wright Medical, Xtant Medical & Cerebrotech, knows execution beats ego every time. He’s scaling Catalyst with discipline, pairing surgeon trust with manufacturing speed. CTO Ephraim, a 20-year med-device vet with 50+ patents and a PhD in Bioengineering, engineered the backbone of Catalyst’s signature precision. CFO Mark Quick brought financial finesse from Orthofix & Canaccord Genuity, while CMO Dr. Miguel Ramirez, Harvard-trained, fellowship at MedStar Union Memorial, anchors the clinical credibility behind the company’s rise.
The product suite reads like a highlight reel. The Archer CSR Total Shoulder System (FDA 2016) set the tone, stemless, ellipsoid, bone-preserving genius that mirrors real anatomy. Then came the Archer R1 Reverse System (FDA 2021) and the Stemmed Anatomic System (FDA 2023). The newest launch, the Catalyst Fracture Shoulder System (FDA 2024; full commercial release Aug 2025), hits the $250M proximal humeral fracture market, the fastest-growing segment in ortho. And with 9+ peer-reviewed studies validating its results, Catalyst’s outcomes are more than marketing, they’re math.
This $15M infusion isn’t fuel for hype; it’s an accelerant for scale. The funds back commercial expansion, surgeon training, and adoption momentum across hospitals and ASCs nationwide. When RC Capital and Mutual Capital Partners keep doubling down, it’s because Catalyst has cracked the medtech code, turning engineering precision into consistent market traction.
